Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Hussein A, Tawbi"'
Autor:
Sang T. Kim, Yanshuo Chu, Mercy Misoi, Maria E. Suarez-Almazor, Jean H. Tayar, Huifang Lu, Maryam Buni, Jordan Kramer, Emma Rodriguez, Zulekha Hussain, Sattva S. Neelapu, Jennifer Wang, Amishi Y. Shah, Nizar M. Tannir, Matthew T. Campbell, Don L. Gibbons, Tina Cascone, Charles Lu, George R. Blumenschein, Mehmet Altan, Bora Lim, Vincente Valero, Monica E. Loghin, Janet Tu, Shannon N. Westin, Aung Naing, Guillermo Garcia-Manero, Noha Abdel-Wahab, Hussein A. Tawbi, Patrick Hwu, Isabella C. Glitza Oliva, Michael A. Davies, Sapna P. Patel, Jun Zou, Andrew Futreal, Adi Diab, Linghua Wang, Roza Nurieva
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/c777865947454d67bd544bb4094e3d5f
Autor:
Paolo A. Ascierto, Christian Blank, Alexander M. Eggermont, Claus Garbe, Jeffrey E. Gershenwald, Omid Hamid, Axel Hauschild, Jason J. Luke, Janice M. Mehnert, Jeffrey A. Sosman, Hussein A. Tawbi, Mario Mandalà, Alessandro Testori, Corrado Caracò, Iman Osman, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-14 (2023)
Abstract The Great Debate session at the 2022 Melanoma Bridge congress (December 1–3) featured counterpoint views from leading experts on five contemporary topics of debate in the management of melanoma. The debates considered the choice of anti-ly
Externí odkaz:
https://doaj.org/article/72b5639fd85f4c0aa3e6387485d98c32
Autor:
Omid Hamid, Diwakar Davar, Keisuke Shirai, Benjamin Izar, Charlotte E Ariyan, Michael K Wong, Jason J Luke, Janis M Taube, Anna C Pavlick, Meghan J Mooradian, Douglas B Johnson, Hussein A Tawbi, Tara C Mitchell, Ryan J Sullivan, April KS Salama, Krista M Rubin, Elizabeth I Buchbinder, Sarah A Weiss, Tina J Hieken, Geoffrey T Gibney, Rajan P Kulkarni, J Keith Tolley, Caressa Valdueza
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regi
Externí odkaz:
https://doaj.org/article/f4721e0504094c6083b6710589696855
Autor:
Irantzu Anzar, Brandon Malone, Pubudu Samarakoon, Ioannis Vardaxis, Boris Simovski, Hugues Fontenelle, Leonardo A. Meza-Zepeda, Richard Stratford, Emily Z. Keung, Melissa Burgess, Hussein A. Tawbi, Ola Myklebost, Trevor Clancy
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionSarcomas are comprised of diverse bone and connective tissue tumors with few effective therapeutic options for locally advanced unresectable and/or metastatic disease. Recent advances in immunotherapy, in particular immune checkpoint inhi
Externí odkaz:
https://doaj.org/article/53e7fb56ac8c4288a24bd58dd3d4124a
Autor:
Jeffrey Sosman, Elad Sharon, Theresa LaVallee, Hussein A Tawbi, Ryan J Sullivan, Harriet M Kluger, Naiyer A Rizvi, David Feltquate
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 7 (2023)
The need for solid clinical definitions of resistance to programmed death 1 or its ligand (PD-(L)1) inhibitors for clinical trial design was identified as a priority by the Society for Immunotherapy of Cancer (SITC). Broad consensus efforts have prov
Externí odkaz:
https://doaj.org/article/b4ec42c072fc44199e543822100f2358
Autor:
Firas Y. Kreidieh, Hussein A. Tawbi
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Despite major advances with immunotherapy and targeted therapy in the past decade, metastatic melanoma continues to be a deadly disease for close to half of all patients. Over the past decade, advancement in immune profiling and a deeper understandin
Externí odkaz:
https://doaj.org/article/b0f46f6db5d7467eac3217493b63e9a8
Autor:
Paolo A. Ascierto, Allison Betof Warner, Christian Blank, Corrado Caracò, Sandra Demaria, Jeffrey E. Gershenwald, Nikhil I. Khushalani, Georgina V. Long, Jason J. Luke, Janice M. Mehnert, Caroline Robert, Piotr Rutkowski, Hussein A. Tawbi, Iman Osman, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 20, Iss 1, Pp 1-20 (2022)
Abstract The Great Debate session at the 2021 Melanoma Bridge virtual congress (December 2–4) featured counterpoint views from experts on seven important issues in melanoma. The debates considered the use of adoptive cell therapy versus use of bisp
Externí odkaz:
https://doaj.org/article/2917377e49964bc4bc0e97f26f613839
Autor:
Sang T. Kim, Yanshuo Chu, Mercy Misoi, Maria E. Suarez-Almazor, Jean H. Tayar, Huifang Lu, Maryam Buni, Jordan Kramer, Emma Rodriguez, Zulekha Hussain, Sattva S. Neelapu, Jennifer Wang, Amishi Y. Shah, Nizar M. Tannir, Matthew T. Campbell, Don L. Gibbons, Tina Cascone, Charles Lu, George R. Blumenschein, Mehmet Altan, Bora Lim, Vincente Valero, Monica E. Loghin, Janet Tu, Shannon N. Westin, Aung Naing, Guillermo Garcia-Manero, Noha Abdel-Wahab, Hussein A. Tawbi, Patrick Hwu, Isabella C. Glitza Oliva, Michael A. Davies, Sapna P. Patel, Jun Zou, Andrew Futreal, Adi Diab, Linghua Wang, Roza Nurieva
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-19 (2022)
Abstract Immune checkpoint inhibitors are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Management of arthritis-irAE is challenging because immunomodulatory therapy for arthritis should not impede antitu
Externí odkaz:
https://doaj.org/article/eafab2babacd4730b744815d6b4763df
Autor:
Dirk Schadendorf, Caroline Robert, Antoni Ribas, Reinhard Dummer, Paolo A Ascierto, Georgina V Long, Daniel Gusenleitner, Eduard Gasal, Hussein A Tawbi, Alexander Savchenko, Jan C Brase, Paul D Nathan, James Garrett, Keith T Flaherty, Güllü Görgün
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/8882610ebdfd455191e99301f24137f9
Autor:
Dai Ogata, Lauren E. Haydu, Isabella C. Glitza, Sapna P. Patel, Hussein A. Tawbi, Jennifer L. McQuade, Adi Diab, Suhendan Ekmekcioglu, Michael K. Wong, Michael A. Davies, Rodabe N. Amaria
Publikováno v:
Cancer Medicine, Vol 10, Iss 7, Pp 2293-2299 (2021)
Abstract Background Anti‐programmed cell death protein 1 (PD‐1) antibodies are a standard treatment for metastatic melanoma patients. However, the understanding of the efficacy of anti‐PD‐1 for acral melanoma (AM) and mucosal melanoma (MM) is
Externí odkaz:
https://doaj.org/article/978825aa55664d048e71fed80d5c0d69